Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × talquetamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 29 Recurrence 4 Hematologic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1 Leukemia, Plasma Cell 1 Infections 1 Immunoglobulin Light-chain Amyloidosis 1 Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 21 blinatumomab 16 Cytarabine 14 fludarabine 13 Azacitidine 11 venetoclax 9 fludarabine phosphate 9 Blood Specimen Collection 8 Rituximab 7 Methotrexate 7 Dexamethasone 7 Daunorubicin 7 Lenalidomide 6 Vincristine 5 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Liquid Biopsy 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Doxorubicin 3 Cladribine 3 Chemotherapy, Adjuvant 3 Busulfan 3 Asparaginase 3 trastuzumab deruxtecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06993675 2025-08-29

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡